Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 9c; Approves $75M Stock Buyback Plan
August 9, 2016 6:51 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.80, $0.09 better than the analyst estimate of $0.71. Revenue for the quarter came in at $40.9 million versus the consensus estimate of $40.8 million.
On August 2, 2016, the Board of Directors has approved a share repurchase program, under... More
